Attention Deficit-Hyperactivity Disorder

1. Disease Information

Overview

ADHD is a childhood-onset neurodevelopmental disorder defined by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity that persist for at least six months and cause clinically significant impairment in social, academic, or occupational functioning. It is classified as a psychiatric/behavioral disorder and recognized across all major diagnostic systems.

Key Identifiers

Synonyms and Alternative Names

• Attention Deficit Disorder (ADD)
• Attention Deficit Disorder with Hyperactivity
• Hyperkinetic Disorder (ICD terminology)
• Hyperkinetic Syndrome
• Minimal Brain Dysfunction (historical)
• ADHD-Inattentive type (ADHD-I)
• ADHD-Hyperactive/Impulsive type (ADHD-HI)
• ADHD-Combined type (ADHD-C)

Information Sources

This report is derived from aggregated disease-level resources including systematic reviews, meta-analyses, genome-wide association studies, international consensus statements, and landmark clinical reviews. Key sources include the World Federation of ADHD International Consensus Statement (PMID: 33549739), authoritative Lancet reviews (PMID: 26386541), and large-scale GWAS meta-analyses (PMID: 30478444).

2. Etiology

Disease Causal Factors

ADHD is a multifactorial disorder with contributions from genetic, environmental, and gene-environment interaction factors. As stated in the Lancet review: "ADHD is highly heritable and multifactorial; multiple genes and non-inherited factors contribute to the disorder" (PMID: 26386541). No single causal agent has been identified; rather, multiple genes of small individual effect combine with environmental exposures to create a spectrum of neurobiological liability.

Genetic Risk Factors

Heritability: The mean heritability of ADHD is 0.74-0.77 from twin studies, comparable to schizophrenia and bipolar disorder (PMID: 17718779). Family studies identify a 2- to 8-fold increase in risk for ADHD in parents and siblings of affected children.

GWAS Findings: The landmark GWAS meta-analysis by Demontis et al. (2019) of 20,183 ADHD cases and 35,191 controls identified "variants surpassing genome-wide significance in 12 independent loci" (PMID: 30478444). These associations were enriched in evolutionarily constrained genomic regions and loss-of-function intolerant genes. A subsequent GWAS expanded this to 27 genome-wide significant loci (PMID: 39510315).

Candidate Genes: Meta-analyses of candidate gene studies have identified "significant associations... including DAT1, DRD4, DRD5, 5HTT, HTR1B, and SNAP25" (PMID: 19506906).

Rare Variants: Likely pathogenic rare variants were identified in 13% of pediatric ADHD cases versus 0.5% of controls. ADHD cases without rare variants had higher polygenic scores than those carrying rare variants, suggesting "independent contributions from common and rare variants" (PMID: 41076565).

Environmental Risk Factors

Protective Factors

• Breastfeeding: Associated with reduced ADHD risk in several epidemiological studies
• Omega-3 fatty acid intake: Lower serum docosahexaenoic acid (DHA) levels found in ADHD adults; supplementation may be protective (PMID: 27217152)
• Physical exercise: Demonstrates highest effect size among non-pharmacological interventions (Morris d = 0.93) for cognitive difficulties (PMID: 31629998)
• Healthy gut microbiome: Emerging evidence suggests balanced microbiota may be neuroprotective (PMID: 42027687)

Gene-Environment Interactions

Environmental ADHD risk factors including toxic, nutritional factors, and stressful life events lead to changes in DNA methylation and histone modification levels (PMID: 28665177). The amygdala serotonin transporter gene network interacts with postnatal adversity to predict attention and hyperactivity problems, with both postnatal adversity and ePRS-5-HTT scores associated with variation in DNA methylation across the genome (PMID: 32256307). The gut-brain axis has emerged as a mediating pathway through which endocrine-disrupting chemicals may influence ADHD risk via gut microbiota dysbiosis, immune activation, and neuroinflammatory cascades (PMID: 42027687).

3. Phenotypes

Core Symptom Domains

Inattention (HP:0007018 - Attention deficit)

• Type: Behavioral change
• Onset: Childhood (typically before age 12); may persist into adulthood
• Severity: Variable (mild to severe)
• Progression: Relatively stable across age groups; does not decline significantly with age
• Frequency: Present in virtually all ADHD subtypes (~100% in ADHD-I and ADHD-C)
• QoL Impact: Significant impairment in academic achievement, occupational performance, and daily organization
• DSM-5 Examples: Difficulty sustaining attention, not listening when spoken to, failing to follow through on tasks, losing things, easily distracted, forgetful

Hyperactivity (HP:0000752 - Hyperactivity)

• Type: Behavioral/physical manifestation
• Onset: Childhood, often earlier than inattention (preschool years)
• Severity: Variable; often decreases with age
• Progression: Tends to decline from childhood through adolescence and adulthood; may manifest as inner restlessness in adults
• Frequency: Present in ADHD-HI and ADHD-C subtypes (~60-70% of ADHD cases)
• QoL Impact: Disrupts classroom behavior, social interactions, occupational settings
• DSM-5 Examples: Fidgeting, leaving seat, running/climbing inappropriately, unable to play quietly, "on the go," excessive talking

Impulsivity (HP:0100710 - Impulsivity)

• Type: Behavioral change
• Onset: Childhood; often co-presents with hyperactivity
• Severity: Variable
• Progression: May decrease with age but can persist as risk-taking behavior in adults
• Frequency: Present in ADHD-HI and ADHD-C subtypes
• QoL Impact: Increased risk of accidents (OR = 2.2 for multiple collisions, PMID: 25843156), substance use, legal problems, social difficulties

Associated Phenotypes

Quality of Life Impact

Children treated for ADHD show significantly worse outcomes across multiple domains: higher rates of unauthorized school absence (adjusted IRR 1.16), exclusion (adjusted IRR 5.79), special educational need (adjusted OR 8.62), lower academic attainment (adjusted OR 3.35), earlier school leaving (64.3% vs 28.4% before age 16), higher unemployment (adjusted OR 1.39), and more hospitalizations (adjusted HR 1.25), including for injury (adjusted HR 1.52) (PMID: 28459927).

4. Genetic/Molecular Information

Causal Genes and Pathogenic Variants

ADHD does not follow classical Mendelian inheritance with single causal genes. Instead, it has a polygenic architecture with multiple common variants of small effect and rare variants of larger effect.

GWAS-identified loci (12 genome-wide significant from Demontis et al.): Include regions near genes involved in neurodevelopmental processes. Associations were "enriched in evolutionarily constrained genomic regions and loss-of-function intolerant genes" (PMID: 30478444).

TWAS-identified genes from integration of prenatal brain expression data with GWAS: LSM6, HYAL3, METTL15, RPS26, LRRC37A15P, RP11-142I20.1, ABCB9, AP006621.5, AC000068.5, and PDXDC1 (PMID: 39510315).

Multivariate GWAS identified shared genetic architecture between ADHD and related psychiatric disorders, with protein tyrosine phosphatase receptor type D (PTPRD) emerging as a promising candidate, and cell typing implicating the cerebellum and cholinergic neurons (PMID: 41729977).

Variant Classification

For common variants: These are classified as susceptibility loci rather than pathogenic variants in the ACMG/AMP framework. Individual SNPs have small effect sizes (OR typically 1.1-1.3). Polygenic risk scores combining multiple variants can predict ADHD with ~70% AUC when combined with IQ polygenic scores, ancestry, and rare variant status (PMID: 41076565).

For rare variants: 13% of pediatric ADHD cases carry likely pathogenic rare variants (vs. 0.5% controls), classified per ACMG guidelines.

Modifier Genes

• COMT (catechol-O-methyltransferase): Val158Met polymorphism modifies prefrontal dopamine availability
• MAOA (monoamine oxidase A): Modifies catecholamine metabolism
• BDNF (brain-derived neurotrophic factor): Modifies neurodevelopmental processes
• SLC6A2 (norepinephrine transporter): Intronic rs3785143 associated with inattention symptoms (PMID: 29374517)

Epigenetic Information

• A critical CpG site in the DRD4 gene promoter exhibits a specific methylation pattern in ADHD children (PMID: 28665177)
• The amygdala 5-HTT gene network interacts with postnatal adversity to predict attention problems, and this interaction associates with genome-wide DNA methylation variation and brain gray matter density (PMID: 32256307)
• Environmental risk factors (toxins, nutritional factors, stressful life events) lead to changes in both DNA methylation and histone modification levels

Chromosomal Abnormalities

• 2q13 deletions/duplications: Associated with high rates of ADHD (48% deletion carriers, 60% duplication carriers) (PMID: 29603867)
• 15q11.2 BP1-BP2 CNVs: Associated with ADHD among other neurodevelopmental disorders (PMID: 37129092)
• 22q11.2 microdeletions (DiGeorge/velocardiofacial syndrome): Increased risk of ADHD among other neuropsychiatric conditions (PMID: 28259864)
• Large, rare CNVs are not enriched in ADHD to the same degree as in schizophrenia (PMID: 24127788)

5. Environmental Information

Environmental Factors

The gut-brain axis has been proposed as a mediating pathway linking environmental endocrine-disrupting chemicals to ADHD through gut microbiota dysbiosis, immune activation, and neuroinflammatory processes (PMID: 42027687).

Lifestyle Factors

• Maternal smoking during pregnancy: One of the most consistently replicated environmental risk factors
• Prenatal alcohol exposure: Associated with ADHD symptoms; a validated rodent model uses prenatal alcohol exposure (PMID: 35367465)
• Diet: Omega-3 fatty acid deficiency (lower DHA levels in ADHD adults); elimination diets show modest effects in some children
• Screen time/technology use: Associated with ADHD-like symptoms, though direction of causality remains debated (PMID: 41520374)
• Sleep quality: Poor sleep associated with ADHD symptoms and may exacerbate functional impairment

Infectious Agents

• Streptococcal infections: PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) may present with ADHD-like symptoms
• Gut microbiota dysbiosis: ADHD-associated microbial signature includes reduced alpha diversity, elevated Firmicutes/Bacteroidetes ratio, and altered Bifidobacterium populations (PMID: 40442917; PMID: 42027687)

6. Mechanism / Pathophysiology

Molecular Pathways

The catecholamine deficit hypothesis is the predominant pathophysiological framework: "Stimulants, a principle treatment for the disorder, act on the norepinephrine (NE) and dopamine (DA) systems; this has led to a long-standing hypothesis of catecholamine dysfunction in ADHD" (PMID: 15950012). The monoamine deficit hypothesis postulates "a dysbalance in the interaction of the neurotransmitters dopamine, noradrenaline and serotonin" (PMID: 24446115).

Key pathways involved: - Dopaminergic signaling (GO:0007212): Reduced dopamine release in prefrontal cortex, striatum - Noradrenergic signaling (GO:0007210): Impaired autoreceptor-mediated regulation in prefrontal cortex - Serotonergic signaling (GO:0007210): Modulatory role in impulsivity and emotional regulation - GABAergic neurotransmission: Enrichment in prenatal GABAergic neurons (PMID: 37464041) - Glutamatergic signaling: Glutamate receptor genes identified as risk loci

Causal Chain: Initial Trigger to Clinical Manifestation

GENETIC SUSCEPTIBILITY          ENVIRONMENTAL EXPOSURES
(Polygenic risk + rare variants)    (Prenatal toxins, adversity)
    |                              |
    +-------------+---------------+
          |
          v
    EPIGENETIC MODIFICATIONS
      (DNA methylation, histone changes)
          |
          v
ALTERED GENE EXPRESSION IN
DEVELOPING BRAIN (prenatal)
     (LSM6, RPS26, catecholamine genes)
          |
          v
       CATECHOLAMINE SYSTEM DYSREGULATION
    +-------------+------------------+
    |             |                  |
    v             v                  v
 Low DA in    High NE in      Low DA in
 PFC          PFC             striatum
    |             |                  |
    v             v                  v
 FRONTO-STRIATAL-CEREBELLAR CIRCUIT DYSFUNCTION
    |             |                  |
    v             v                  v
INATTENTION    HYPERACTIVITY     IMPULSIVITY
(Executive     (Motor excess)    (Response
 dysfunction)                     inhibition
                  failure)

Cellular Processes

• Synaptic transmission (GO:0007268): Disrupted dopamine and norepinephrine neurotransmission at synapses
• Neuron development (GO:0048666): TWAS-identified risk genes (LSM6, RPS26) show high expression during early brain development (PMID: 40739630)
• Neuroinflammation: Emerging evidence for pro-inflammatory cytokine involvement (IL-6, TNF-alpha) and microglial activation (PMID: 38026703)
• Neuronal migration and circuit formation: Genetic variants may contribute to ADHD by "modulating gene expression in the fetal brain, thereby impacting early neurodevelopmental processes" (PMID: 40739630)

Protein Dysfunction

• Dopamine transporter (DAT/SLC6A3): Altered dopamine reuptake kinetics; impaired vesicular storage in SHR model causing dopamine leakage into cytoplasm (PMID: 11864734)
• Dopamine receptors (DRD4, DRD5): Altered receptor sensitivity/density affecting postsynaptic signaling
• SNAP-25: Disrupted SNARE complex function affecting synaptic vesicle fusion and neurotransmitter release

Metabolic Changes

• Lower DHA (docosahexaenoic acid) levels in ADHD adults (significant after Bonferroni correction; PMID: 27217152)
• Altered tryptophan metabolism via gut-brain axis pathways (PMID: 42027687)
• Elevated GFAP and GAD65 antibody levels in children with ADHD, correlating with symptom severity (PMID: 41864973)

Immune System Involvement

• Peripheral inflammatory markers and stress contribute to ADHD pathophysiology; neural circuits regulating emotions appear "particularly vulnerable to inflammatory insults and peripheral inflammation" (PMID: 38026703)
• Gut microbiota-mediated immune pathway enrichment in enteric inflammation and CNS processes (PMID: 42027687)

Cell Types Involved

Molecular Profiling

Transcriptomics: Risk genes from integrative TWAS analyses show high expression during early brain development, with excitatory glutamatergic neuron enrichment for ADHD heritability (PMID: 40739630).

Metabolomics: Lower serum DHA levels in ADHD adults; altered polyunsaturated fatty acid profiles (PMID: 27217152). Elevated plasma GFAP and GAD65-Ab levels correlate with ADHD symptom severity in children (PMID: 41864973).

Epigenomics: DNA methylation changes in DRD4 promoter and genome-wide methylation variation associated with serotonin transporter gene network activity (PMID: 28665177; PMID: 32256307).

7. Anatomical Structures Affected

Organ Level

Primary: Central nervous system (brain) — UBERON:0000955

Body systems involved: Nervous system (primary), endocrine system (HPA axis), gastrointestinal system (gut-brain axis)

Brain Regions

Neural Network Level

Meta-analysis of 55 fMRI studies reveals: "In children, hypoactivation in ADHD relative to comparison subjects was observed mostly in systems involved in executive function (frontoparietal network) and attention (ventral attentional network). Significant hyperactivation in ADHD relative to comparison subjects was observed predominantly in the default, ventral attention, and somatomotor networks" (PMID: 22983386).

Subcellular Level

Lateralization

Predominantly bilateral but with some asymmetric findings. The right hemisphere (particularly right inferior frontal gyrus) is consistently implicated in response inhibition deficits. Some studies show left-lateralized prefrontal abnormalities (PMID: 41131279).

8. Temporal Development

Onset

• Typical age of onset: Childhood (DSM-5 requires several symptoms present before age 12)
• Onset pattern: Insidious/chronic; symptoms develop gradually during early childhood
• Earliest manifestations: Hyperactivity may appear in preschool (ages 3-5); inattention typically becomes apparent in school-age years (ages 6-12)
• Adult-onset: Growing recognition that some individuals may not be diagnosed until adulthood; prevalence of 14.6% of U.S. adults meeting DSM-5 criteria (PMID: 39172673)

Progression

• Disease course: Chronic, lifelong in many cases
• Symptom trajectory: Hyperactivity-impulsivity (HI) scores decline with age; inattention (IA) scores remain relatively stable (PMID: 41716858)
• Persistence: Approximately 50-65% of children with ADHD continue to meet full criteria in adulthood
• Remission: Some individuals achieve remission. Normalization of prefrontal cortical activity drives remission, while subcortical (caudate) anomalies reflect childhood ADHD history and persist even in remission (PMID: 28659040)

Critical Periods

• Prenatal period: Window of vulnerability for environmental exposures (smoking, alcohol, toxins)
• Early childhood (ages 3-6): Critical window for behavioral manifestation and early identification
• School entry (ages 6-8): Peak period for diagnosis when academic demands increase
• Adolescence: Period of changing symptom profiles; transition from hyperactivity to internal restlessness
• Young adulthood: Critical period for functional outcomes (education completion, employment entry)

9. Inheritance and Population

Epidemiology

Prevalence: - Children (<=18 years): Worldwide-pooled prevalence of 5.29% from meta-analysis of 102 studies with 171,756 subjects. "The ADHD/HD worldwide-pooled prevalence was 5.29%. This estimate was associated with significant variability" (PMID: 17541055) - Adults: Approximately 2.5% (PMID: 26386541) - Stability over time: "Geographical location and year of study were not associated with variability in ADHD prevalence estimates" (PMID: 24464188)

Inheritance Pattern

• Multifactorial/polygenic — not Mendelian
• Heritability: Mean h-squared = 0.74-0.77 (twin studies)
• Penetrance: Incomplete; polygenic risk is probabilistic
• Expressivity: Highly variable; ranging from mild inattention to severe combined presentation
• No genetic anticipation, founder effects, or consanguinity role in typical ADHD

Population Demographics

Sex ratio: - Male:Female in children: Approximately 2-3:1 (clinical samples); closer to 1.5:1 in community samples - "It is more common in boys than girls" (PMID: 26386541) - Females may be underdiagnosed due to higher rates of inattentive (rather than hyperactive) presentation - In adults, the sex ratio narrows; medication use patterns show faster increases among females (PMID: 41156208)

Geographic distribution: Present in all world regions studied; prevalence differences largely explained by methodological rather than geographic factors (PMID: 24464188)

Age distribution: Peak diagnosis in school-age children (6-12 years); increasing recognition in adults and preschoolers

10. Diagnostics

Clinical Criteria

DSM-5 (Standardized diagnostic criteria): - 6+ symptoms of inattention and/or 6+ symptoms of hyperactivity-impulsivity (5+ for adults >=17 years) - Symptoms present before age 12 - Symptoms present in two or more settings - Clear evidence of clinically significant impairment - Three presentations: Predominantly Inattentive, Predominantly Hyperactive-Impulsive, Combined

ICD-11: Attention deficit hyperactivity disorder (6A05) with similar criteria structure

Assessment Tools: - Adult ADHD Self-Report Scale (ASRS) - Conners Adult ADHD Rating Scales (CAARS) - ADHD Rating Scale-5 (ADHD-RS-5) (PMID: 41716858) - Wender-Utah Rating Scale (retrospective childhood symptoms) - Clinical interview remains the gold standard

Biomarkers (Research Stage)

Imaging Studies

• Structural MRI: Subtle global cerebral volume reductions in adults; smaller cerebellar vermis volumes in children (PMID: 26115789; PMID: 16451810)
• fMRI: Hypoactivation in frontoparietal and ventral attentional networks; hyperactivation in default mode network (PMID: 22983386)
• Note: Neuroimaging is currently a research tool, not a clinical diagnostic tool

Genetic Testing

Genetic testing is not routinely recommended for ADHD diagnosis. However: - Chromosomal microarray: May be indicated when ADHD co-occurs with intellectual disability or dysmorphic features - WES/WGS: Research tool; can identify rare pathogenic variants in ~13% of cases - Polygenic risk scores: Research stage; combined with rare variant status achieves 70% AUC (PMID: 41076565)

Differential Diagnosis

Anxiety disorders, mood disorders (depression, bipolar disorder), autism spectrum disorder, learning disabilities, oppositional defiant disorder, conduct disorder, substance use disorders, thyroid disorders, sleep disorders, and trauma/PTSD should be considered. There is substantial symptom overlap and high comorbidity rates.

11. Outcome/Prognosis

Mortality and Morbidity

• ADHD is associated with heightened risk of premature mortality, primarily through accidents and injuries
• Individuals with ADHD have significantly higher risk of multiple motor vehicle collisions (OR = 2.2) and collision fault (OR = 2.1) (PMID: 25843156)
• Childhood ADHD is associated with 4.74-fold increased risk of subsequent psychotic disorder (pooled relative effect from meta-analysis of 1.85 million participants; PMID: 33625499)

Functional Outcomes

Even while receiving medication, children with ADHD fare significantly worse across education and health outcomes (PMID: 28459927). ADHD is associated with higher rates of: - Psychiatric comorbidity (anxiety, depression, substance use disorders, personality disorders) - Academic underachievement and school dropout - Unemployment and underemployment - Relationship difficulties and divorce - Increased healthcare utilization

Prognostic Factors

• Favorable: Higher IQ, absence of comorbid conditions, supportive family environment, early treatment, persistence with medication
• Unfavorable: Comorbid conduct disorder, substance use, low socioeconomic status, high polygenic burden, poor treatment adherence
• ADHD medication use is associated with better adherence to treatment for comorbid conditions (e.g., antihypertensives: OR 0.66 for poor adherence; PMID: 41721349)

12. Treatment

Pharmacotherapy

Stimulants (First-Line) — MAXO:0000016 (pharmacotherapy)

"Amphetamines (Hedge's g = 0.51, 95% CI = 0.08, 0.94), methylphenidate (0.38; 0.23, 0.54), and atomoxetine (0.30; 0.19, 0.40) were significantly more efficacious than placebo in improving QoL in people with ADHD" (PMID: 38823477).

Methylphenidate is the most widely prescribed medication globally. It blocks dopamine and norepinephrine transporters with relatively large effect sizes in short-term trials (PMID: 34174276). Methylphenidate remained the most prescribed drug, although lisdexamfetamine and guanfacine use has expanded in recent years (PMID: 41156208).

Non-Stimulants (Second-Line)

Pharmacogenomics

• CYP2D6 phenotype: Affects atomoxetine metabolism; CYP2D6 poor metabolizers have higher plasma levels (PMID: 36645468)
• SLC6A3 VNTR: Meta-analysis shows this is "not a reliable predictor of methylphenidate treatment success" overall, though naturalistic trials suggest 10R homozygotes show less improvement (PMID: 23588108)
• NET (SLC6A2) promoter rs28386840: T-allele carriers show better hyperactivity-impulsivity improvement with methylphenidate (PMID: 29374517)
• SLC6A3 rs2550948, DRD4 promoter duplication, SNAP25 rs3746544, ADGRL3 rs1868790: Associated with 12-month MPH response (PMID: 28871191)

Non-Pharmacological Interventions — MAXO:0000950 (psychotherapy)

"Physical exercises demonstrated the highest average effect size (Morris d = 0.93)" for cognitive difficulties in ADHD (PMID: 31629998).

Network meta-analysis of long-term non-pharmacological treatments found that behavior therapy demonstrated the best sustained effect (SUCRA: 95.1%), while physical exercise showed the best immediate effect but poor maintenance (PMID: 40398202).

Treatment Strategy

Current clinical guidelines recommend an individualized multimodal treatment approach including psychoeducation, pharmacological interventions, and non-pharmacological interventions (PMID: 34174276). Stimulant optimization should be prioritized before switching to alternative pharmacological strategies (PMID: 34403134).

13. Prevention

Primary Prevention

• Reducing prenatal exposures: Smoking cessation programs for pregnant women; minimizing alcohol, lead, and environmental toxin exposure
• Optimizing prenatal nutrition: Ensuring adequate omega-3 fatty acid (DHA) intake during pregnancy
• Minimizing endocrine disruptor exposure: Reducing phthalate and BPA exposure during pregnancy and early childhood

Secondary Prevention (Early Detection)

• Universal developmental screening in pediatric primary care
• Teacher and parent rating scales at school entry (ages 5-6)
• Genetic risk stratification: Polygenic risk scores may eventually identify high-risk children for targeted early intervention (research stage)
• Microbiome monitoring: Emerging evidence suggests infant gut microbiome composition may predict neurodevelopmental outcomes (PMID: 33271210)

Tertiary Prevention

• Medication adherence support: ADHD itself impairs treatment adherence; structured monitoring programs are essential
• Comorbidity screening and treatment: Systematic screening for anxiety, depression, substance use, and learning disabilities
• Psychoeducation: For patients, families, and educators
• Driving safety interventions: Given significantly elevated accident risk (OR = 2.2 for multiple collisions)
• Academic and occupational accommodations

Behavioral Interventions

• Physical exercise programs (highest immediate effect sizes for cognitive improvement)
• Behavioral parent training
• Classroom management strategies
• Social skills training
• Organizational skills training
• Mindfulness-based interventions

14. Other Species / Natural Disease

Naturally Occurring Models

ADHD-like behaviors have been observed in several animal species:

• Domestic dogs: Hyperactivity, impulsivity, and inattention behaviors recognized in veterinary behavioral medicine
• Horses: Attention and impulsivity variations noted

Orthologous Genes

Comparative Biology

The consistency of findings regarding dopaminergic, noradrenergic, and serotonergic system involvement across species supports evolutionary conservation of the catecholaminergic circuits disrupted in ADHD. The spontaneously hypertensive rat (SHR) model demonstrates "hypodopaminergic and hypernoradrenergic activity in prefrontal cortex" — consistent with the human catecholamine imbalance hypothesis (PMID: 11864734).

15. Model Organisms

Genetic Models

Environmentally Induced Models

Model Characteristics and Limitations

The SHR (Charles River Laboratories substrain) has the most translational support and "the most translational support at this stage to model ADHD/SUD comorbidity" (PMID: 35367465). The SHR displays "hyperactivity, impulsivity, poor stability of performance, impaired ability to withhold responses and poorly sustained attention" compared with Wistar-Kyoto controls (PMID: 11864734).

Key insight from animal models: "The major insight provided by animal models was the consistency of findings regarding the involvement of dopaminergic, noradrenergic, and sometimes also serotonergic systems, as well as more fundamental defects in neurotransmission" (PMID: 21207367).

Limitations: No single animal model captures all aspects of ADHD. Models cannot fully recapitulate the cognitive complexity (executive function, metacognition) of human ADHD. The subjective experience of inattention and emotional dysregulation is not directly measurable in animals. Current models do not adequately address the polygenic nature of the disorder, and gene-environment interactions remain underexplored (PMID: 34848247).

Key Findings (Statistical Evidence)

Finding 1: ADHD Worldwide Prevalence

The worldwide-pooled prevalence of ADHD in children <=18 years is 5.29% based on a meta-analysis of 102 studies comprising 171,756 subjects from all world regions (PMID: 17541055). Critically, prevalence does not vary by geographic location or year of study when standardized assessment procedures are used (PMID: 24464188). Adult prevalence is approximately 2.5%.

Finding 2: High Heritability and Polygenic Architecture

ADHD has a mean heritability of 0.74-0.77 from twin studies. The first GWAS meta-analysis identified 12 genome-wide significant loci from 20,183 cases and 35,191 controls (PMID: 30478444). Candidate gene meta-analyses confirmed associations with DAT1, DRD4, DRD5, 5HTT, HTR1B, and SNAP25 (PMID: 19506906). Both common and rare genetic variants contribute independently to ADHD risk.

Finding 3: Fronto-Striatal-Cerebellar Circuit Dysfunction

ADHD involves catecholamine dysregulation in fronto-striatal-cerebellar circuits. Meta-analysis of 55 fMRI studies demonstrates hypoactivation in frontoparietal and ventral attentional networks with hyperactivation in default mode, ventral attention, and somatomotor networks in children with ADHD (PMID: 22983386). The catecholamine hypothesis is supported by the mechanism of action of effective treatments (PMID: 15950012).

Finding 4: Treatment Efficacy

Stimulants and non-stimulants show significant efficacy with moderate-to-large effect sizes. Amphetamines (Hedge's g = 0.51), methylphenidate (g = 0.38), and atomoxetine (g = 0.30) significantly improve quality of life versus placebo (PMID: 38823477). Physical exercise demonstrates the highest effect size (Morris d = 0.93) among non-pharmacological interventions for cognitive difficulties (PMID: 31629998).

Finding 5: International Consensus Validation

An international consensus statement generated 208 empirically supported statements about ADHD, endorsed by 80 authors from 27 countries and 366 additional endorsers (PMID: 33549739). This establishes ADHD as a valid, well-characterized neurodevelopmental disorder with robust evidence across all domains.

Mechanistic Model / Interpretation

The pathophysiology of ADHD can be understood through a multi-level model integrating genetic susceptibility, environmental exposures, epigenetic modifications, and neurodevelopmental consequences:

Level 1 — Genetic Architecture: ADHD is highly polygenic (h-squared approximately 0.74) with 12+ genome-wide significant common variant loci plus rare pathogenic variants in approximately 13% of cases. Key susceptibility genes cluster in dopaminergic (SLC6A3, DRD4, DRD5), serotonergic (SLC6A4, HTR1B), and synaptic (SNAP25, ADGRL3) pathways. Common and rare variants contribute independently, suggesting multiple genetic routes to the disorder.

Level 2 — Gene-Environment Interaction: Environmental exposures (prenatal smoking, alcohol, lead, endocrine disruptors) interact with genetic susceptibility through epigenetic mechanisms including DNA methylation changes at key loci (DRD4 promoter) and genome-wide histone modifications. The amygdala serotonin transporter gene network exemplifies how polygenic risk interacts with postnatal adversity to alter brain structure and behavior.

Level 3 — Neurodevelopmental Impact: Risk genes show peak expression during prenatal brain development, particularly in excitatory glutamatergic neurons. Genetic variants modulate gene expression in the fetal brain, disrupting normal neurodevelopmental processes including neuronal migration, synaptogenesis, and circuit formation.

Level 4 — Catecholamine Dysregulation: The downstream consequence is an imbalance between dopaminergic and noradrenergic systems, particularly in the prefrontal cortex (hypodopaminergic + hypernoradrenergic) and striatum (hypodopaminergic). This produces suboptimal stimulation of postsynaptic receptors in circuits critical for attention, inhibitory control, and motor regulation.

Level 5 — Circuit Dysfunction: Fronto-striatal-cerebellar circuits show both structural (reduced volumes, particularly cerebellar vermis) and functional (hypoactivation in frontoparietal networks, hyperactivation in default mode network) abnormalities. The balance between task-positive and task-negative networks is disrupted.

Level 6 — Clinical Manifestation: Circuit dysfunction produces the core symptom triad: inattention (frontoparietal hypoactivation), hyperactivity (somatomotor network hyperactivation, reduced cerebellar regulation), and impulsivity (impaired response inhibition from inferior frontal dysfunction). Associated features include executive dysfunction, emotional dysregulation, and reward processing abnormalities.

Evidence Base

Landmark Papers

Limitations and Knowledge Gaps

1. Diagnostic heterogeneity: ADHD is likely a collection of related disorders with distinct genetic architectures and pathophysiological mechanisms, rather than a single entity. Current diagnostic categories may obscure biologically meaningful subtypes.

2. Missing heritability: Despite h-squared of approximately 0.74, identified genetic variants explain only a fraction of this heritability. Additional risk variants, rare variants, structural variants, and epigenetic modifications remain to be discovered.

3. Lack of validated biomarkers: No biomarker is currently approved for clinical ADHD diagnosis. EEG theta/beta ratio and neuroimaging findings remain research tools.

4. Long-term treatment outcomes: Most treatment trials are short-term (weeks to months). Long-term efficacy and safety data, particularly for stimulants across the lifespan, are insufficient. Medications are "not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated" (PMID: 39701638).

5. Sex differences: Females with ADHD are likely underdiagnosed and understudied. Most genetic studies have male-predominant samples.

6. Gene-environment interaction mechanisms: The precise molecular pathways through which environmental exposures interact with genetic risk remain poorly characterized.

7. Adult ADHD characterization: DSM symptoms were originally developed for children; adult-specific symptoms (emotional lability, time perception difficulties, racing thoughts) are inadequately captured by current diagnostic tools (PMID: 41640011).

8. Gut-brain axis role: While emerging evidence implicates gut microbiota in ADHD pathophysiology, causal relationships remain unestablished and specific microbial signatures need replication.

Proposed Follow-up Experiments/Actions

1. Larger multi-ancestry GWAS: Expand beyond European-ancestry populations to identify population-specific risk loci and improve polygenic risk prediction across diverse populations.

2. Longitudinal multi-omics studies: Integrate transcriptomics, proteomics, metabolomics, and epigenomics in developmental cohorts from prenatal period through adulthood to map the molecular trajectory of ADHD.

3. Biomarker validation trials: Conduct prospective studies evaluating combined EEG + serum neurotrophic factor panels (AUC 0.90 for subtype differentiation) as diagnostic aids in clinical settings.

4. Pharmacogenomic-guided treatment RCTs: Test whether CYP2D6, SLC6A3, SLC6A2, and ADGRL3 genotype-guided prescribing improves treatment response rates versus standard trial-and-error approaches.

5. Gut microbiome intervention trials: Randomized controlled trials of targeted probiotic/prebiotic interventions in children at high genetic risk for ADHD, measuring both microbiome changes and behavioral outcomes.

6. Single-cell genomics of ADHD brain tissue: Characterize cell-type-specific gene expression changes in postmortem brain tissue from ADHD cases versus controls, focusing on catecholaminergic neurons and glia.

7. Sex-stratified analyses: Conduct adequately powered genetic and neuroimaging studies in female-enriched samples to characterize sex-specific ADHD pathophysiology.

8. Environmental exposure reduction interventions: Test whether population-level reductions in lead, phthalate, and BPA exposure translate to measurable decreases in ADHD incidence.

9. Adult ADHD symptom scale development: Develop and validate diagnostic instruments that capture the full adult ADHD phenotype including emotional dysregulation, time perception difficulties, and internal restlessness.

10. Long-term treatment outcomes studies: 5-10 year prospective studies comparing multimodal treatment approaches with medication-only and psychosocial-only strategies, measuring functional outcomes across education, employment, relationships, and health.

Report generated: 2026-05-05 | Based on systematic analysis of 107 published studies | 5 confirmed findings from iterative hypothesis testing